B. Clotet

发表

A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS.

G. Stingl, B. Vandercam, P. Phillips, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hepatitis C virus NS3/4A quasispecies diversity in acute hepatitis C infection in HIV‐1 co‐infected patients

C. Tural, S. Franco, J. Rockstroh, 2014, Journal of viral hepatitis.

Safety and efficacy of an induction dose of pegylated interferon alpha‐2a on early hepatitis C virus kinetics in HIV/HCV co‐infected patients: the CORAL‐1 multicentre pilot study

B. Clotet, C. Tural, C. Quereda, 2007, Journal of viral hepatitis.

Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection

U. Spengler, J. Trebicka, J. Rockstroh, 2019, HIV medicine.

Comparison of two different strategies of treatment with zoledronate in HIV‐infected patients with low bone mineral density: single dose versus two doses in 2 years

E. Negredo, J. Puig, N. Pérez-Álvarez, 2015, HIV medicine.

Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio

E. Negredo, M. Larrousse, A. Curran, 2015, HIV medicine.

Hyaluronic acid, transforming growth factor‐β1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co‐infection

C. Tural, I. Ojanguren, C. Rey-Joly, 2009, Journal of viral hepatitis.

Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations

C. Tural, J. Miro, V. Soriano, 2004, Journal of viral hepatitis.

Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts *

J. Montaner, B. Clotet, E. Negredo, 2008, HIV medicine.

Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co‐infected patients

G. Sirera, C. Tural, I. Ojanguren, 2003, Journal of viral hepatitis.

Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study

E. Negredo, M. Larrousse, A. Curran, 2013, HIV medicine.

Cloxacillin-lnduced Leukopenia

B. Clotet, J. Rubiés-prat, A. M. Vea, 1985 .

Antithrombin III contribution to cholestasis differential diagnosis: its correlation with one stage prothrombin time and factor V.

J. Torras, J. Alloza, J. Juncà, 1980, Clinical and laboratory haematology.

Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations

A. Horban, R. Landman, B. Clotet, 2005, HIV medicine.

Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV‐1‐infected subjects with dyslipidaemia

E. Negredo, J. Puig, B. Clotet, 2017, HIV medicine.

Transient Treatment Exclusively Containing Nucleoside Analogue Reverse Transcriptase Inhibitors in Highly Antiretroviral-Experienced Patients Preserves Viral Benefit When a Fully Active Therapy Was Initiated

J. Martinez-Picado, E. Negredo, S. Videla, 2008, HIV clinical trials.

Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment‐naïve HIV‐1‐infected patients (the ARTEN study)

D. Podzamczer, V. Soriano, P. Reiss, 2011, HIV medicine.

Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV‐1‐infected patients with multidrug‐resistant virus: a multicentre pilot study

J. Schapiro, J. Martinez-Picado, E. Negredo, 2008, HIV medicine.

HTLV-I in Spain

V. Soriano, J. Tor, B. Clotet, 1990, The Lancet.

Progression of liver fibrosis in HIV/hepatitis C virus‐coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline

B. Clotet, C. Tural, I. Ojanguren, 2014, HIV medicine.

48-week outcomes following switch from AZT/3TC to FTC/TDF (TVD) vs. continuing on AZT/3TC: 48-week interim analysis of the RECOMB trial

E. Negredo, A. Curran, F. Pulido, 2008 .

AIDS and Kaposi sarcoma pre-1979

V. Soriano, R. Root-Bernstein, R. Pujol, 1990, The Lancet.

Prevalence, evolution, and related risk factors of kidney disease among Spanish HIV-infected individuals

E. Negredo, J. Bonet, R. Romero, 2017, Medicine.

[Recommendations of the Spanish AIDS Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral treatment in adult patients with human immunodeficiency virus infection in 2002].

J. Miro, J. Gatell, E. Martinez, 2002, Enfermedades infecciosas y microbiologia clinica.

Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV

T. Harrer, A. Winston, E. Harrer, 2023, Scientific Reports.

Diagnosis of myocarditis

B. Clotet, J. V. Momplet, J. Borrell, 1982 .